Voyager Therapeutics, Inc.

Leveraging genetics to treat neurological diseases

Founded 2014

Lexington, United States 163 employees IPO Total: $324.50M Biotechnology, Health Care +1

Voyager Therapeutics, Inc. (Nasdaq: VYGR), founded in 2014, is a pioneering biotechnology company headquartered in the United States. Their compelling slogan, "Leveraging genetics to treat neurological diseases," encapsulates their mission to innovate in the field of neurological health.

Voyager focuses on utilizing human genetics to alter the trajectory of and potentially cure neurological ailments, with a robust pipeline addressing conditions like Alzheimer’s, Friedreich’s ataxia, Parkinson’s, and ALS. Their proprietary TRACER™ AAV capsid discovery platform stands out as a key technological asset, enhancing genetic medicine delivery with high brain penetration capabilities.

The company collaborates with notable industry leaders such as Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. to advance its programs. Their latest financial milestone includes a $100.00M Post IPO Equity investment on 01 January 2024, underscoring strong market confidence in their innovative approach.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$100.00M	-		01 Jan 2024
Post-IPO Debt	$39.00M	1	Neurocrine Biosciences	01 Jan 2023
IPO	$80.50M	-		01 Nov 2015
Series B	$60.00M	6	Casdin Capital, Wellington Management +4	01 Apr 2015
Spinout	$45.00M	1	Third Rock Ventures	01 Feb 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

$100.00M

01 Jan 2024

Post-IPO Debt

$39.00M

Neurocrine Biosciences

01 Jan 2023

IPO

$80.50M

01 Nov 2015

Series B

$60.00M

Casdin Capital, Wellington Management +4

01 Apr 2015

Spinout

$45.00M

Third Rock Ventures

01 Feb 2014

FAQ About Voyager Therapeutics, Inc.

Leveraging genetics to treat neurological diseases

Voyager Therapeutics, Inc. was founded in 2014.

Voyager Therapeutics, Inc. is headquartered in Lexington, United States.

Voyager Therapeutics, Inc. operates in Biotechnology, Health Care and Life Sciences. Its work centres on Gene Therapy, AAV Gene Therapy, Vector Optimization and CNS Diseases. Its customers include Patients with neurological diseases, Healthcare providers specializing in neurology and Research institutions in the field of genetics.

Voyager Therapeutics, Inc. has a B2B and Platform business model. Its revenue comes from Licensing, Product Sales and Performance Based.

Voyager Therapeutics, Inc. has approximately 163 employees.

Voyager Therapeutics, Inc. has completed 5 funding rounds, raising a total of $324.50M. The latest funding stage is IPO.

Voyager Therapeutics, Inc. offers: Development of transformative medicines, Implementation of gene therapy approaches, Advancement of genetic therapies for neurological conditions, Research and development in neurogenetics.

Top alternatives and competitors to Voyager Therapeutics, Inc. include Caraway Therapeutics, Inc., Disarm Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Voyager Therapeutics, Inc. and Caraway Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Voyager Therapeutics, Inc.

General Information

Discover More

About Voyager Therapeutics, Inc.

Services & Products

Target Customers

Funding Rounds & Investors (5)

Voyager Therapeutics, Inc. Alternatives & Competitors

FAQ About Voyager Therapeutics, Inc.